• 1. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 2. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 3. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694

Recent Advances in the Application of 6-Bromo-4-chloropyridine-2-carbonitrile (CAS: 1206248-51-2) in Chemical Biology and Pharmaceutical Research

6-Bromo-4-chloropyridine-2-carbonitrile (CAS: 1206248-51-2) has emerged as a key building block in medicinal chemistry and drug discovery due to its versatile reactivity and potential for structural diversification. Recent studies have highlighted its importance as a precursor for the synthesis of various biologically active compounds, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief synthesizes the latest findings regarding this compound's applications, synthetic methodologies, and biological evaluations.

In synthetic chemistry, 6-Bromo-4-chloropyridine-2-carbonitrile has been utilized as a multifunctional intermediate in palladium-catalyzed cross-coupling reactions. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its effectiveness in Suzuki-Miyaura couplings, enabling the rapid assembly of diverse pyridine derivatives with potential anticancer activity. The bromo and chloro substituents at the 6- and 4-positions respectively provide orthogonal reactivity, allowing for sequential functionalization, while the cyano group at the 2-position offers additional modification possibilities.

Pharmaceutical research has particularly focused on derivatives of 6-Bromo-4-chloropyridine-2-carbonitrile as potential kinase inhibitors. Recent preclinical studies have shown that properly functionalized analogs exhibit promising activity against JAK2 and FLT3 kinases, which are important targets in myeloproliferative disorders and acute myeloid leukemia. Molecular modeling studies suggest that the pyridine core provides optimal binding geometry, while the halogen substituents contribute to favorable hydrophobic interactions in the ATP-binding pocket.

In antimicrobial applications, researchers have reported that 6-Bromo-4-chloropyridine-2-carbonitrile derivatives demonstrate significant activity against drug-resistant bacterial strains. A 2024 publication in Bioorganic & Medicinal Chemistry Letters described a series of compounds where the pyridine scaffold was elaborated with various heterocyclic systems, resulting in molecules with potent activity against methicillin-resistant Staphylococcus aureus (MRSA) with MIC values in the low micromolar range.

The compound's safety profile and ADME properties have also been investigated in recent studies. Metabolic stability assays indicate that the pyridine-2-carbonitrile core demonstrates favorable pharmacokinetic properties, with moderate plasma protein binding and good membrane permeability. These characteristics make it an attractive scaffold for further drug development efforts.

Looking forward, researchers are exploring novel synthetic routes to 6-Bromo-4-chloropyridine-2-carbonitrile that could improve yield and scalability. Continuous flow chemistry approaches have shown particular promise in recent pilot studies, potentially addressing some of the challenges associated with traditional batch synthesis methods. Additionally, computational chemistry approaches are being employed to predict new bioactive derivatives and optimize existing leads.

In conclusion, 6-Bromo-4-chloropyridine-2-carbonitrile (CAS: 1206248-51-2) continues to be a valuable intermediate in pharmaceutical research, with recent studies expanding its applications in targeted drug discovery. Its versatility as a synthetic building block combined with the demonstrated biological activity of its derivatives suggests it will remain an important compound in chemical biology research for the foreseeable future.

• 1252046-16-4(6-Bromo-3-chloropicolinonitrile)
• 122918-25-6(6-bromopyridine-2-carbonitrile)
• 1227958-97-5(2-Bromo-6-(cyano-13C, 15N)pyridine)
• 1643575-56-7(2-Bromo-6-cyanopyridine-d3)
• 1206249-38-8(2-bromo-4-chloro-6-methylpyridine)
• 1256805-11-4((6-Bromo-4-chloropyridin-2-YL)methanamine)
• 1256823-45-6(6-Bromo-5-chloropyridine-2-carbonitrile)
• 36953-44-3(5-Bromo-1H-pyrrole-2-carbonitrile)
• 2460492-26-4(2-bromo-4-chloro-6-(methyl-d3)pyridine-3,5-d2)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)